عرض بسيط للتسجيلة

المؤلفKaddoura, Rasha
المؤلفOmar, Amr S.
المؤلفIbrahim, Mohamed Izham Mohamed
المؤلفAlkhulaifi, Abdulaziz
المؤلفLorusso, Roberto
المؤلفElsherbini, Hagar
المؤلفSoliman, Osama
المؤلفCaliskan, Kadir
تاريخ الإتاحة2023-08-29T10:21:47Z
تاريخ النشر2021
اسم المنشورJournal of Cardiothoracic and Vascular Anesthesia
المصدرScopus
الرقم المعياري الدولي للكتاب10530770
معرّف المصادر الموحدhttp://dx.doi.org/10.1053/j.jvca.2021.01.019
معرّف المصادر الموحدhttp://hdl.handle.net/10576/46993
الملخصObjectives: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) provides a temporary support system for patients with cardiogenic shock refractory to conventional medical therapies. It has been reported that levosimendan may facilitate VA-ECMO weaning and improve survival. The primary objective of this review was to examine the effect of levosimendan use on VA-ECMO weaning and mortality in critically ill patients on VA-ECMO. Design: MEDLINE, EMBASE, and CENTRAL were searched. A pair of reviewers identified eligible clinical trials. Two reviewers extracted data and independently assessed the risk of bias. A random-effect model was used to combine data. The primary outcome was the success of weaning from VA-ECMO. Measurements and Main Results: Seven studies of observational design, including a total of 630 patients, were selected in the final analysis. The sample size ranged from ten-to-240 patients, with a mean age between 53 and 65 years, and more than half of them underwent cardiac surgeries. The VA-ECMO durations varied between four and 11.6 days. Overall, levosimendan use was significantly associated with successful weaning compared with control (odds ratio [OR] 2.89, 95% CI, 1.53-5.46; poverall effect = 0.001); I2 = 49%). For survival, six studies (n = 617) were included in the meta-analysis involving 326 patients in the levosimendan group and 291 in the comparator group. Pooled results showed a significantly higher survival rate in the levosimendan group (OR 0.46, 95% CI, 0.30-0.71; poverall effect = 0.0004; I2 = 20%). Conclusions: Levosimendan therapy was significantly associated with successful weaning and survival benefit in patients with cardiogenic or postcardiotomy shock needing VA-ECMO support for severe cardiocirculatory compromise. To date, there is limited literature and absence of evidence from randomized trials addressing the use of levosimendan in VA-ECMO weaning. This study may be considered a hypothesis-generating research for randomized controlled trials to confirm its findings.
راعي المشروعThe authors thank Dr Klaus Distelmaier and Dr Georg Goliasch for their support in providing additional data of their published study. All the authors declare that they have no competing interests. The study was approved by Hamad Medical Corporation through the Medical Research Center. Kindly, to the following to the acknowledgement section: Open Access funding provided by the Qatar National Library
اللغةen
الناشرElsevier
الموضوعcardiogenic shock
ECLS
extracorporeal life support
extracorporeal membrane oxygenation
levosimendan
weaning
العنوانThe Effectiveness of Levosimendan on Veno-Arterial Extracorporeal Membrane Oxygenation Management and Outcome: A Systematic Review and Meta-Analysis
النوعArticle Review
الصفحات2483-2495
رقم العدد8
رقم المجلد35
dc.accessType Abstract Only


الملفات في هذه التسجيلة

الملفاتالحجمالصيغةالعرض

لا توجد ملفات لها صلة بهذه التسجيلة.

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة